(Q37763406)

22 August 2017

1 reference

title

The role of central noradrenergic dysregulation in anxiety disorders: evidence from clinical studies (English)

1 reference

22 August 2017

3

A R Lingford-Hughes

1 reference

22 August 2017

N J Kalk

1

1 reference

22 August 2017

D J Nutt

series ordinal

2

1 reference

22 August 2017

language of work or name

English

0 references

publication date

8 June 2010

1 reference

Journal of Psychopharmacology

22 August 2017

1 reference

22 August 2017

25

1 reference

22 August 2017

1

1 reference

22 August 2017

3-16

1 reference

Blunted growth hormone response to clonidine in patients with generalized anxiety disorder

22 August 2017

1 reference

https://api.crossref.org/works/10.1177%2F0269881110367448

Endocrine, cardiovascular, and behavioral responses to clonidine in patients with panic disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110367448

Response to hyperventilation and 5.5% CO2 inhalation of subjects with types of specific phobia, panic disorder, or no mental disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110367448

Inhalation of 35% CO(2) results in activation of the HPA axis in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110367448

An open clinical trial of reboxetine in the treatment of social phobia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110367448

Does the Brain Noradrenaline Network Mediate the Effects of the CO2 Challenge?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110367448

Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110367448

Comparison of the treatment with paroxetine and reboxetine in panic disorder: a randomized, single-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110367448

Randomized placebo-controlled trial of escitalopram and venlafaxine XR in the treatment of generalized anxiety disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110367448

Postmortem locus coeruleus neuron count in three American veterans with probable or possible war-related PTSD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110367448

Noradrenergic receptor sensitivity in obsessive compulsive disorder: II. Cortisol response to acute clonidine administration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110367448

Noradrenergic mechanisms in stress and anxiety: I. Preclinical studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110367448

Noradrenergic mechanisms in stress and anxiety: II. Clinical studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110367448

Anxious and depressive disorders and their comorbidity: effect on central nervous system noradrenergic function

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110367448

Platelet alpha 2-adrenergic receptor binding and plasma catecholamines. Before and during imipramine treatment in patients with panic anxiety.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110367448

Adrenergic status in anxiety disorders: platelet alpha 2-adrenergic receptor binding, blood pressure, pulse, and plasma catecholamines in panic and generalized anxiety disorder patients and in normal subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110367448

Alpha 2-adrenergic and opiate receptor blockade. Synergistic effects on anxiety in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110367448

Noradrenergic function in panic anxiety. Effects of yohimbine in healthy subjects and patients with agoraphobia and panic disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110367448

Platelet alpha-2-receptor binding and adenylate cyclase activity in panic disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110367448

Neurobiological mechanisms of panic anxiety: biochemical and behavioral correlates of yohimbine-induced panic attacks

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110367448

Noradrenergic function in generalized anxiety disorder: effects of yohimbine in healthy subjects and patients with generalized anxiety disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110367448

Persistence of blunted human growth hormone response to clonidine in fluoxetine-treated patients with panic disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110367448

Challenge tests: assessment of the noradrenergic and GABA systems in depression and anxiety disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110367448

The efficacy of reboxetine in the treatment-refractory patients with panic disorder: an open label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110367448

Safety and efficacy of escitalopram in the long-term treatment of generalized anxiety disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110367448

Plasma and cerebrospinal fluid 3-methoxy-4-hydroxyphenylethylene glycol (MHPG) as indices of brain norepinephrine metabolism in primates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110367448

Cerebrospinal fluid levels of monoamine metabolites in panic disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110367448

Human sympathetic nerve biology: parallel influences of stress and epigenetics in essential hypertension and panic disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110367448

Measurement of overall and cardiac norepinephrine release into plasma during cognitive challenge.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110367448

Growth-hormone response to clonidine in panic disorder patients in comparison to patients with major depression and healthy controls.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110367448

A cerebrospinal fluid study of the pathophysiology of panic disorder associated with alcoholism

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110367448

CSF Norepinephrine Concentrations in Posttraumatic Stress Disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110367448

Physiological changes during carbon dioxide inhalation in patients with panic disorder, major depression, and premenstrual dysphoric disorder: evidence for a central fear mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110367448

Relationship between plasma and cerebrospinal fluid norepinephrine and dopamine metabolites in a nonhuman primate

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110367448

Platelet alpha2-adrenergic receptor coupling efficiency to Gi protein in subjects with post-traumatic stress disorder and normal controls

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110367448

Adrenergic receptor function in panic disorder. II. Neutrophil beta 2 receptors: Gs protein coupling, effects of imipramine treatment and relationship to treatment outcome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110367448

Characteristics of norepinephrine and clonidine displacement of [3H]yohimbine binding to platelet alpha2-adrenoreceptors in healthy volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110367448

Relationship between imidazoline and alpha2-adrenoceptors involved in the sympatho-inhibitory actions of centrally acting antihypertensive agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110367448

Multicenter double-blind comparison of sertraline and desipramine for concurrent obsessive-compulsive and major depressive disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110367448

Sympathetic activity relates to adenosine A(2A) receptor gene variation in blood-injury phobia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110367448

Noradrenergic function in obsessive-compulsive disorder: behavioral and neuroendocrine responses to clonidine and comparison to healthy controls

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110367448

Growth hormone and cortisol secretion after oral clonidine in healthy adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110367448

Stimulation by alpha-adrenergic mechanisms of the secretion of growth hormone-releasing factor (GRF) from perifused rat hypothalamus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110367448

Comorbidity of mood and anxiety disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110367448

Acute carbon dioxide exposure in healthy adults: evaluation of a novel means of investigating the stress response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110367448

Central noradrenergic involvement in yohimbine excitation of acoustic startle: effects of DSP4 and 6-OHDA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110367448

False suffocation alarms, spontaneous panics, and related conditions. An integrative hypothesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110367448

Cerebral noradrenaline spillover and its relation to muscle sympathetic nervous activity in healthy human subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110367448

Alpha 2-adrenoreceptor status in obsessive-compulsive disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110367448

Platelet alpha2-adrenoreceptors in obsessive-compulsive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110367448

A pilot study of noradrenergic and HPA axis functioning in PTSD vs. panic disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110367448

Yohimbine facilitated acoustic startle in combat veterans with post-traumatic stress disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110367448

Plasma norepinephrine kinetics in patients with posttraumatic stress disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110367448

Short-term serotonergic but not noradrenergic antidepressant administration reduces attentional vigilance to threat in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110367448

Altered central alpha 2-adrenoceptor sensitivity in panic disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110367448

Platelet binding studies in panic disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110367448

Modulation of hyperreactivity to 35% CO2 after one week of treatment with paroxetine and reboxetine: a double-blind, randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110367448

Influence of endurance training on energy intake, norepinephrine kinetics, and metabolic rate in older individuals.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110367448

A randomized controlled trial of venlafaxine ER and paroxetine in the treatment of outpatients with panic disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110367448

Effects of yohimbine in obsessive compulsive disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110367448

The central hypotensive effect of clonidine; Studies in tetraplegie subjcets

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110367448

Mirtazapine versus fluoxetine in the treatment of panic disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110367448

Serotonergic neurons as carbon dioxide sensors that maintain pH homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110367448

Norepinephrine transporter gene (NET) variants in patients with panic disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110367448

Growth hormone response to clonidine in untreated depressed patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110367448

Reboxetine and citalopram in panic disorder: a single-blind, cross-over, flexible-dose pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110367448

Higher cerebrospinal fluid homovanillic acid levels in depressed patients with comorbid posttraumatic stress disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110367448

Sertraline, paroxetine, and venlafaxine in refugee posttraumatic stress disorder with depression symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110367448

Abnormal noradrenergic function in posttraumatic stress disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110367448

Yohimbine use in a natural setting: effects on posttraumatic stress disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110367448

Reboxetine versus fluvoxamine in the treatment of motor vehicle accident-related posttraumatic stress disorder: a double-blind, fixed-dosage, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110367448

Effects of reboxetine on anxiety, agitation, and insomnia: results of a pooled evaluation of randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110367448

Advances in understanding the anxiety disorders: the cognitive-affective neuroscience of 'false alarms'.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110367448

Heart rate and plasma norepinephrine responsivity to orthostatic challenge in anxiety disorders. Comparison of patients with panic disorder and social phobia and normal control subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110367448

Mapping of the norepinephrine transporter in the human brain using PET with (S,S)-[18F]FMeNER-D2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110367448

Sensitivity to carbon dioxide in drug-naïve subjects with post-traumatic stress disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110367448

Yohimbine: a clinical review

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110367448

Lactic acid response to caffeine in panic disorder: comparison with social phobics and normal controls.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110367448

Estimation of endogenous noradrenaline release in rat brain in vivo using [3H]RX 821002.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110367448

Behavioral and physiologic effects of short-term and long-term administration of clonidine in panic disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110367448

Blunted growth hormone response to clonidine in panic disorder patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110367448

Reboxetine, a selective norepinephrine reuptake inhibitor, is an effective and well-tolerated treatment for panic disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110367448

Sympathetic activity in patients with panic disorder at rest, under laboratory mental stress, and during panic attacks.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110367448

Reboxetine: a pharmacologically potent, selective, and specific norepinephrine reuptake inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110367448

Alpha 2-adrenoceptor modulation of 5-HT biosynthesis in the rat brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110367448

Urinary Excretion of Cortisol, Norepinephrine, Testosterone, and Melatonin in Panic Disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110367448

21 January 2018

Identifiers

DOI

10.1177/0269881110367448

1 reference

release_k6caodzksfak5lr3aykjiwwf44

22 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/k6caodzksfak5lr3aykjiwwf44

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference